NEW YORK – August 20, 2018 – Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the publication of an investigator-initiated study from Duke University and The Mayo Clinic demonstrating that despite the widespread use of formula-derived estimates of plasma volume in heart failure patients, these methods are inaccurate compared to measured volume using the company’s BVA-100 blood volume measurement diagnostic. The study, “Calculated Estimates of Plasma Volume in Patients with Chronic Heart Failure – Comparison to Measured Volumes” was recently published in the Journal of Cardiac Failure.
“This study shows that indirect assessments of plasma volume or blood volume are limited by their inaccuracy. Our study shows that this is true for formula based volume assessment or the measure of hemoconcentration and similarly poor correlation has previously been shown for the physical exam and even intra-cardiac pressure assessments,” said Marat Fudim, MD, Fellow, Division of Cardiology, Duke University and one of the study authors.
“This study confirms that Daxor’s technology of direct volume measurement is of the highest clinical utility in diagnosing fluid volume overload in heart failure patients,” said Daxor’s CEO Michael Feldschuh. “Many physicians have relied on formula-based estimates of plasma volume overload. This study quantified the very poor correlation of these calculated estimates with direct measured volume of the patients, which could potentially hinder optimal treatment and result in re-hospitalization or even death.”
In the study, plasma volume was measured using Daxor’s BVA-100 in 110 patients with clinically stable chronic heart failure. These measurements were correlated using two different plasma volume estimation techniques. The first was the Kaplan-Hakim formula, which calculates blood volume using a formula calculating hematocrit relative to dry body weight. The second, the Strauss formula, estimates changes in plasma volume over time using hemoglobin and hematocrit measurement. The study ultimately showed neither formula demonstrated an accurate blood volume estimate compared to the BVA-100. These formulas varied in their accuracy between just 16 and 68 percent compared to Daxor’s BVA-100, the acknowledged ‘gold-standard’ of volume measurement.
”This study is further evidence showing why BVA-guided treatment of heart failure leads to significantly better results in mortality and readmission. Proxy measures such as formulas, hemodynamics, and clinical assessment alone do not allow the individualization of care needed for optimal treatment of HF. Based on these results, we continue to work to educate physicians about direct blood volume measurement and to expand the availability of the BVA-100 across the US,” said Jonathan Feldschuh, Daxor’s chief technology officer.
About Daxor Corporation
Daxor Corporation is an innovative medical instrumentation and biotechnology company. We manufacture the BVA-100 Blood Volume Analyzer, the first instrument approved by the FDA to provide rapid direct measurement of a patient’s blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. Ultimately the company’s mission is to help hospitals and physicians incorporate DAXOR’s BVA-100 diagnostic significantly improve the quality of patient care. For more information please visit our website at https://www.daxor.com.
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Sr. Managing Partner